'It's Totally Irresponsible': Canadian Ethicist Slams Rogue Russian's Plan to Edit Human Embryos
By Gemma Buck,
National Post
| 07. 08. 2019
Canadian bioethicists and genetics experts are speaking out against Denis Rebrikov, the Russian molecular biologist who plans — in defiance of international scientific norms — to alter human embryos using CRISPR gene-editing technology to allow prospective parents with genetic deafness to conceive a child who can hear.
“We are putting ourselves on the path to changing the human evolutionary story. This is not up to one scientist. It’s not up to a group of scientists or a group of political elites. It’s up to all of us,” said Françoise Baylis, a professor of philosophy and bioethics at Dalhousie University who serves on a World Health Organization committee that is developing global standards and oversight for editing of the human genome.
The ethical implications of this kind of rogue science are wide-ranging and nuanced, Baylis explained. But the obvious ones are dire: Making genetic changes to eggs, sperm, or early embryos, collectively called the human germline, affects not only the eventual person these cells may become, but also their offspring.Though there is a “spectrum” of views among scientists and ethicists about... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...